{"id":40143,"date":"2026-10-27T14:01:12","date_gmt":"2026-10-27T13:01:12","guid":{"rendered":"https:\/\/mabdesign.fr\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/"},"modified":"2026-10-27T15:10:55","modified_gmt":"2026-10-27T14:10:55","slug":"cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/","title":{"rendered":"Prostate cancer: from established peptides to emerging biotherapies"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"40143\" class=\"elementor elementor-40143 elementor-40137\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7fc1a69 e-flex e-con-boxed e-con e-parent\" data-id=\"7fc1a69\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7a0ec25 elementor-widget elementor-widget-text-editor\" data-id=\"7a0ec25\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>For Movember, MabDesign offers a new look at market dynamics and projects in development for prostate cancer, focusing on the diversification of therapeutic approaches, the main targets being explored, and recent developments in the clinical pipeline. Movember is an initiative dedicated to men&#8217;s health, supporting awareness and research on prostate cancer. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ce4a3b7 e-flex e-con-boxed e-con e-parent\" data-id=\"ce4a3b7\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-aa7126d elementor-widget elementor-widget-text-editor\" data-id=\"aa7126d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Prostate cancer remains a big health problem worldwide. According to the GLOBOCAN 2024 data published by IARC in July 2026, it&#8217;s estimated that there will be 1.55 million new cases globally in 2024, with nearly 420,000 deaths. Also, about 5.18 million people were still alive in 2024 after being diagnosed with prostate cancer in the previous five years.  <\/p>\n<p><strong>Epidemiological data<\/strong><\/p>\n<ul>\n<li>1.55 million new cases worldwide in 2024<\/li>\n<li>420,000 deaths worldwide in 2024<\/li>\n<li>5.18 million people alive who were diagnosed in the past five years.<\/li>\n<\/ul>\n<p><strong>Market and pipeline of biotherapies in prostate cancer<\/strong><\/p>\n<p>The MabDesign analysis identifies 81 marketed product references and 262 unique references in the clinical pipeline, from phase 0 to phase III. These 262 products correspond to 302 product \u00d7 indication pairs \u2013 the same product can be developed in multiple clinical contexts.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b1391ef e-flex e-con-boxed e-con e-parent\" data-id=\"b1391ef\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-189de0d elementor-widget elementor-widget-image\" data-id=\"189de0d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"609\" height=\"268\" src=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-094733.png\" class=\"attachment-large size-large wp-image-40104\" alt=\"\" srcset=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-094733.png 609w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-094733-300x132.png 300w\" sizes=\"(max-width: 609px) 100vw, 609px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2f307e5 elementor-widget elementor-widget-text-editor\" data-id=\"2f307e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The comparison highlights two very different profiles. The marketed portfolio is largely dominated by peptides and their combinations, which account for 78 of the 81 listed references. It is also heavily influenced by generics: 61 out of 81 references, or 75.3%, are coded as generics.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-372d777 e-flex e-con-boxed e-con e-parent\" data-id=\"372d777\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-efca734 e-con-full e-flex e-con e-child\" data-id=\"efca734\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-332e909 elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"332e909\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">A much more diverse clinical pipeline<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6f2c734 elementor-widget elementor-widget-text-editor\" data-id=\"6f2c734\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The landscape is noticeably different when looking at products in clinical development. ADCs make up the leading category, with 64 out of 262 products, or 24.4% of the clinical pipeline. They&#8217;re followed by monoclonal antibodies (14.9%), cell therapies (14.5%), bi- or multispecific formats (12.6%), and radiopharmaceuticals (11.1%).  <\/p>\n<p><strong>A pipeline mainly focused on phases I and II<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-991f3c3 elementor-widget elementor-widget-image\" data-id=\"991f3c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"520\" height=\"284\" src=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-095056.jpg\" class=\"attachment-large size-large wp-image-40106\" alt=\"\" srcset=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-095056.jpg 520w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-095056-300x164.jpg 300w\" sizes=\"(max-width: 520px) 100vw, 520px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-915447b elementor-widget elementor-widget-text-editor\" data-id=\"915447b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The analysis by product \u00d7 indication pair shows a strong concentration of programs in the middle stages of clinical development. Out of 302 clinical pairs, 152 are in phase II and 119 in phase I, compared to 18 in phase III and 13 in phase 0. So phase II represents 50.3% of the developments listed, while only 6% have reached phase III.  <\/p>\n<p>This breakdown shows a pipeline that is well-supplied but still mostly in the early stages of development.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9362077 elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"9362077\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">PSMA dominates the target landscape<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7ace592 elementor-widget elementor-widget-image\" data-id=\"7ace592\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"599\" height=\"274\" src=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-104311.png\" class=\"attachment-large size-large wp-image-40108\" alt=\"\" srcset=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-104311.png 599w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-104311-300x137.png 300w\" sizes=\"(max-width: 599px) 100vw, 599px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-02bb557 elementor-widget elementor-widget-text-editor\" data-id=\"02bb557\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The diversification of methods comes with a variety of targeting strategies. PSMA\/FOLH1 appears to be the most represented target in the extraction, with 57 product \u00d7 indication pairs, ahead of B7-H3\/CD276 (27), CD3 (26), PD-1 (19), and CTLA-4 (15).<\/p>\n<p>PSMA is not limited to radioligands either: in the extract, this target is being explored across several platforms, including radiopharmaceuticals, genetically modified cell therapies, bi-\/multi-specific formats, and ADCs.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bfe11c8 elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"bfe11c8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">A development still largely focused on the frontlines<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9ff98c7 elementor-widget elementor-widget-image\" data-id=\"9ff98c7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"585\" height=\"206\" src=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-104606.png\" class=\"attachment-large size-large wp-image-40110\" alt=\"\" srcset=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-104606.png 585w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-104606-300x106.png 300w\" sizes=\"(max-width: 585px) 100vw, 585px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5a7376d elementor-widget elementor-widget-text-editor\" data-id=\"5a7376d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Among the 213 clinical products for which a line of treatment is specified, 159 appear in the second line, 64 in the third line, and 27 in the first line; 10 are also associated with an adjuvant context.<\/p>\n<p><em>These categories aren&#8217;t mutually exclusive, the same product can be studied in several processing lines.<\/em><\/p>\n<p>This shift towards advanced lines is consistent with the role of mCRPC \u2014 metastatic castration-resistant prostate cancer \u2014 which is the primary targeted indication, with 129 out of 302 product \u00d7 indication pairs (42.7%).<\/p>\n<p><strong>Recent milestones that show the diversification of approaches<\/strong><\/p>\n<p>Several recent developments concretely illustrate this diversification of therapeutic approaches.<\/p>\n<ul>\n<li>In September 2025, pasritamig (JNJ-78278343) entered the phase III KLK2-comPAS study (NCT07164443) in mCRPC. This bispecific T-cell engager antibody targets KLK2 on tumor cells and CD3 on T lymphocytes. The study is currently listed as Enrolling by Johnson &#038; Johnson. <\/li>\n<li>On July 31, 2026, the FDA granted an indication extension for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for patients with PSMA+ metastatic prostate cancer who are androgen pathway modulation-na\u00efve\/sensitive, previously called mHSPC. This decision expands the use of this radioligand therapy to an earlier stage of metastatic disease. The ^177Lu-PSMA-617 program became part of Novartis&#8217; portfolio following the acquisition of Endocyte, completed in December 2018.  <\/li>\n<li>Finally, risvutatug rezetecan (GSK5764227 \/ HS-20093), an ADC targeting B7-H3, is now being evaluated in phase III in the EMBOLD Prostate-302 study (NCT07802704) in patients with mCRPC. GSK&#8217;s official registry indicates a study that started in September 2026 and is currently recruiting. GSK holds the development and commercialization rights outside mainland China, Hong Kong, Macao, and Taiwan under a licensing agreement with Hansoh Pharma signed in December 2023. <\/li>\n<\/ul>\n<p>These examples illustrate an innovation landscape where ADCs, T-cell engagers, and radioligands are moving forward at the same time, each with different targeting strategies and clinical positions.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7f85e4e e-flex e-con-boxed e-con e-parent\" data-id=\"7f85e4e\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-1629280 e-con-full e-flex e-con e-child\" data-id=\"1629280\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fe1af31 elementor-widget elementor-widget-heading\" data-id=\"fe1af31\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Download our infographic<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-67dfac7 elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"67dfac7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h6 class=\"elementor-heading-title elementor-size-default\">Take a quick look at the main market and pipeline numbers in prostate cancer: development stages, treatment types, lines of therapy, key targets, and examples of recent clinical and regulatory milestones.<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7dbe063 elementor-widget__width-initial elementor-widget elementor-widget-image\" data-id=\"7dbe063\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"633\" height=\"895\" src=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-01-144238.png\" class=\"attachment-large size-large wp-image-39738\" alt=\"\" srcset=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-01-144238.png 633w, https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-01-144238-212x300.png 212w\" sizes=\"(max-width: 633px) 100vw, 633px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cfd7c28 elementor-align-center elementor-widget elementor-widget-button\" data-id=\"cfd7c28\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Breast-cancer-pipeline_one-pager_EN-1.pdf\" target=\"_blank\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Dowload.PDF<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5b2916f e-con-full e-flex e-con e-child\" data-id=\"5b2916f\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8e2e2c5 elementor-widget elementor-widget-heading\" data-id=\"8e2e2c5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"> Do you want to know more?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-45af870 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"45af870\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>MabDesign supports players in biotherapy with their Business Intelligence challenges through market studies, pipeline and competitor analyses, technology benchmarks, and customized strategic analyses.<\/p>\n<p>Looking to better understand a market, pipeline, or competitive environment?<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d5b9421 elementor-align-center elementor-widget__width-initial elementor-widget elementor-widget-button\" data-id=\"1d5b9421\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"mailto:marketstudy@mabdesign.fr?subject=Offre%20de%20services%20\" target=\"_blank\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Let's talk about your needs <\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e1483b5 elementor-widget elementor-widget-text-editor\" data-id=\"e1483b5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h6>Sources :<br\/><br\/><strong>Sources :<\/strong> IARC \u2013 GLOBOCAN 2024, donn\u00e9es publi\u00e9es en juillet 2026 ; Analyse MabDesign bas\u00e9e sur GlobalData, extraction du 19 octobre 2026 ; FDA ; registres et communications officielles Johnson &#038; Johnson, Novartis et GSK, consult\u00e9s en octobre 2026.<\/h6>\n<p><span style=\"text-align: var(--text-align); color: var( --e-global-color-text );\">Date &#8211; November 2026<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4308228 e-flex e-con-boxed e-con e-parent\" data-id=\"4308228\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-3e0f6c1 e-flex e-con-boxed e-con e-parent\" data-id=\"3e0f6c1\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>MabDesign&#8217;s market analyses give you a monthly look at market trends and development projects for a given indication or technology, to better understand the ever-changing market of biopharmaceuticals and bioproduction. This month, a look at the market and ongoing projects for the treatment of chronic inflammatory bowel diseases (IBD). <\/p>\n","protected":false},"author":10,"featured_media":40115,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"page_builder":"","footnotes":""},"categories":[88,119],"tags":[163,98,508,141],"class_list":["post-40143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bio-hub-en","category-market-analysis-en","tag-biomedicaments-en","tag-innovation-en","tag-maladies-inflammatoires","tag-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Market Prostate cancer: from established peptides to emerging biotherapies - MabDesign<\/title>\n<meta name=\"description\" content=\"On the occasion of Movember, MabDesign is offering a new look at market dynamics and projects in development for prostate cancer, with a focus on the diversification of treatment approaches, key targets being explored, and recent developments in the clinical pipeline. Movember is an initiative dedicated to men&#039;s health, notably supporting awareness and research on prostate cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Market Prostate cancer: from established peptides to emerging biotherapies - MabDesign\" \/>\n<meta property=\"og:description\" content=\"On the occasion of Movember, MabDesign is offering a new look at market dynamics and projects in development for prostate cancer, with a focus on the diversification of treatment approaches, key targets being explored, and recent developments in the clinical pipeline. Movember is an initiative dedicated to men&#039;s health, notably supporting awareness and research on prostate cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T13:01:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T14:10:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-105100.png\" \/>\n\t<meta property=\"og:image:width\" content=\"594\" \/>\n\t<meta property=\"og:image:height\" content=\"841\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Megan De Klerk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Megan De Klerk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/\"},\"author\":{\"name\":\"Megan De Klerk\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#\\\/schema\\\/person\\\/7d394796253feb2ba298dfad4fa99509\"},\"headline\":\"Prostate cancer: from established peptides to emerging biotherapies\",\"datePublished\":\"2026-10-27T13:01:12+00:00\",\"dateModified\":\"2026-10-27T14:10:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/\"},\"wordCount\":838,\"publisher\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mabdesign.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Screenshot-2026-10-27-105100.png\",\"keywords\":[\"biom\u00e9dicaments\",\"innovation\",\"maladies inflammatoires\",\"market\"],\"articleSection\":[\"Bio-hub\",\"Market analysis\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/\",\"url\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/\",\"name\":\"Market Prostate cancer: from established peptides to emerging biotherapies - MabDesign\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mabdesign.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Screenshot-2026-10-27-105100.png\",\"datePublished\":\"2026-10-27T13:01:12+00:00\",\"dateModified\":\"2026-10-27T14:10:55+00:00\",\"description\":\"On the occasion of Movember, MabDesign is offering a new look at market dynamics and projects in development for prostate cancer, with a focus on the diversification of treatment approaches, key targets being explored, and recent developments in the clinical pipeline. Movember is an initiative dedicated to men's health, notably supporting awareness and research on prostate cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mabdesign.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Screenshot-2026-10-27-105100.png\",\"contentUrl\":\"https:\\\/\\\/mabdesign.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Screenshot-2026-10-27-105100.png\",\"width\":594,\"height\":841},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prostate cancer: from established peptides to emerging biotherapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/mabdesign.fr\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/logo-mabdesign.png\",\"contentUrl\":\"https:\\\/\\\/mabdesign.fr\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/MabDesign_fr\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/mabdesign\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/#\\\/schema\\\/person\\\/7d394796253feb2ba298dfad4fa99509\",\"name\":\"Megan De Klerk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9ff3f294928a6268c82045b0204e961e6177b0f2e4b0d1a6a51f8dae4c6cbc4e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9ff3f294928a6268c82045b0204e961e6177b0f2e4b0d1a6a51f8dae4c6cbc4e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9ff3f294928a6268c82045b0204e961e6177b0f2e4b0d1a6a51f8dae4c6cbc4e?s=96&d=mm&r=g\",\"caption\":\"Megan De Klerk\"},\"url\":\"https:\\\/\\\/mabdesign.fr\\\/en\\\/author\\\/megan-de-klerk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Market Prostate cancer: from established peptides to emerging biotherapies - MabDesign","description":"On the occasion of Movember, MabDesign is offering a new look at market dynamics and projects in development for prostate cancer, with a focus on the diversification of treatment approaches, key targets being explored, and recent developments in the clinical pipeline. Movember is an initiative dedicated to men's health, notably supporting awareness and research on prostate cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/","og_locale":"en_US","og_type":"article","og_title":"Market Prostate cancer: from established peptides to emerging biotherapies - MabDesign","og_description":"On the occasion of Movember, MabDesign is offering a new look at market dynamics and projects in development for prostate cancer, with a focus on the diversification of treatment approaches, key targets being explored, and recent developments in the clinical pipeline. Movember is an initiative dedicated to men's health, notably supporting awareness and research on prostate cancer.","og_url":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/","og_site_name":"MabDesign","article_published_time":"2026-10-27T13:01:12+00:00","article_modified_time":"2026-10-27T14:10:55+00:00","og_image":[{"width":594,"height":841,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-105100.png","type":"image\/png"}],"author":"Megan De Klerk","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Megan De Klerk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/"},"author":{"name":"Megan De Klerk","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/7d394796253feb2ba298dfad4fa99509"},"headline":"Prostate cancer: from established peptides to emerging biotherapies","datePublished":"2026-10-27T13:01:12+00:00","dateModified":"2026-10-27T14:10:55+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/"},"wordCount":838,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-105100.png","keywords":["biom\u00e9dicaments","innovation","maladies inflammatoires","market"],"articleSection":["Bio-hub","Market analysis"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/","url":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/","name":"Market Prostate cancer: from established peptides to emerging biotherapies - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-105100.png","datePublished":"2026-10-27T13:01:12+00:00","dateModified":"2026-10-27T14:10:55+00:00","description":"On the occasion of Movember, MabDesign is offering a new look at market dynamics and projects in development for prostate cancer, with a focus on the diversification of treatment approaches, key targets being explored, and recent developments in the clinical pipeline. Movember is an initiative dedicated to men's health, notably supporting awareness and research on prostate cancer.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-105100.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/10\/Screenshot-2026-10-27-105100.png","width":594,"height":841},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/cancer-de-la-prostate-des-peptides-etablis-aux-biotherapies-emergentes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Prostate cancer: from established peptides to emerging biotherapies"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/7d394796253feb2ba298dfad4fa99509","name":"Megan De Klerk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9ff3f294928a6268c82045b0204e961e6177b0f2e4b0d1a6a51f8dae4c6cbc4e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9ff3f294928a6268c82045b0204e961e6177b0f2e4b0d1a6a51f8dae4c6cbc4e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9ff3f294928a6268c82045b0204e961e6177b0f2e4b0d1a6a51f8dae4c6cbc4e?s=96&d=mm&r=g","caption":"Megan De Klerk"},"url":"https:\/\/mabdesign.fr\/en\/author\/megan-de-klerk\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/40143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=40143"}],"version-history":[{"count":3,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/40143\/revisions"}],"predecessor-version":[{"id":40146,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/40143\/revisions\/40146"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/40115"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=40143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=40143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=40143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}